Secondary analysis of FINEARTS-HF (5873 patients with HF and LVEF ≥40%): higher baseline bilirubin predicted worsening HF events and CV death; finerenone vs placebo lowered bilirubin and ALP, and its benefit did not differ by bilirubin level (P interaction 0.43).
Secondary analysisn = 5,873
Butt et al. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF